~~<i id='0F777BC317'><strike id='0F777BC317'><tt id='0F777BC317'><pre id='0F777BC317'></pre></tt></strike></i>~~

Home» explore» focus

focus

author：knowledge 2025-09-27 13:59:27 Page View：82198

AP/Richard Drew

Johnson & Johnson said Monday that it would purchase Ambrx Biopharma for nearly $2 billion, picking up a company specializing in targeted chemotherapy treatments — one of the hottest areas of cancer drug development.

The deal, disclosed as the biopharma field marked the first day of the annual J.P. Morgan Healthcare Conference, extends a recent spate of pharma acquisitions, contributing to hopes that 2024 could be a better year for the industry.

Under the agreement, J&J will pay $28 per share in cash for Ambrx, roughly a 100% premium to the latter’s recent trading price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Why 40% Americans with Parkinson’s don’t see a neurologist
Next article： Duchenne breakthrough therapy leaves behind pioneering families

leisure time

Hepatitis C has a cure — but many Americans still lack access to it

AdobeIn2005,NickVoyleswasdiagnosedwithhepatitisCafterbeingreleasedfromfiveyearsofincarceration.Anurs

Insurance companies sue energy corporation after it was blamed for helping start Colorado wildfire

2:13FILE-TheburnedremainsofahomedestroyedbytheMarshallFireareshown,Jan.7,2022,inLouisville,Colo.OnTh

Peter Hotez and the public health issue of online harassment

AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

Oak trusses raised to roof of fire

0:38AcraneliftsahugeoakframeatNotreDamedePariscathedral,Tuesday,July11,2023inParis.Thepanelsaredueto